fluorecare® cTnI/CK-MB/MyO Diagnostic Kit

To address the global demand for rapid cardiovascular diagnostics, Microprofit Biotech proudly introduces the cTnI/CK-MB/MyO Combo Immunofluorescence Quantitative Assay Kit. Leveraging Fluorescence Immunoassay (FIA) POCT technology, this innovative kit delivers accurate AMI diagnosis in just 15 minutes, surpassing the >60-minute turnaround time of traditional lab tests (CLIA/ECLIA). Designed for emergency rooms, ICUs, and primary care settings, it sets a new standard for efficiency in cardiac care.

Why Test cTnI, MyO, and CK-MB?

1. cTnI (Cardiac Troponin I)

   • Gold Standard for AMI Diagnosis: >95% specificity, endorsed by ESC/ACC guidelines.

2. MyO (Myoglobin)

   • Earliest Biomarker: Detectable within 1–2 hours post-symptom onset, enabling early rule-out.

3. CK-MB (Creatine Kinase-MB)

   • Reinfarction Monitoring: Short half-life (12–24 hours) ideal for detecting reocclusion.

   • Infarct Size Estimation: Peak levels correlate with myocardial damage extent.

Key Advantages

✅ Ultra-Fast Diagnosis, Saving Critical Time

• Results in 15 minutes vs. >60 minutes for central lab tests, drastically reducing door-to-balloon (D2B) time.

✅ Cost-Effective & Streamlined Workflow

• Single-test triplex detection replaces sequential single-marker assays, cutting costs and complexity.

✅ Comprehensive AMI Coverage

• MyO (early screening) → cTnI (confirmation) → CK-MB (reinfarction monitoring) – seamless tracking of AMI progression.

✅ Flexible Sample Types, No Centrifugation

• Compatible with whole blood/serum/plasma, ideal for resource-limited settings.

✅ Certifications

• CE Certified, compliant with ISO 13485.

✅ Reliable & Accurate

• Clinical validation shows >95% concordance with CLIA .

Applications

• ERs & Chest Pain Centers: Rapid triage for ACS protocols.

• ICUs/CCUs: Post-operative myocardial injury monitoring.

• Primary Hospitals & Ambulances: Lab-independent AMI screening.

• Disaster & Battlefield Medicine: Portable for field emergencies.